Displaying drugs 7651 - 7675 of 8037 in total
ATG-101
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile.
Investigational
Matched Description: … ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive …
Luveltamab tazevibulin
Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate. It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer).
Investigational
Matched Description: … [A257414] It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate …
Galidesivir
Galidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus. In animal studies, galidesivir was effective in increasing the survival rates from infections caused by various pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses. In vitro, it displayed broad-spectrum antiviral activity against various negative- and...
Investigational
Matched Description: … [L12039,L12084] Phase 1 clinical trials have begun to determine the safety of this drug in humans. ... [L12042] Because of its activity against other coronaviruses, it may be studied as a potential therapy …
Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)
The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853]. In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection . It...
Investigational
Matched Description: … non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of ... The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding …
Spermidine
Spermidine is a polyamine formed from putrescine. It is found in almost all tissues in association with nucleic acids. It is found as a cation at all pH values, and is thought to help stabilize some membranes and nucleic acid structures. It is a precursor of spermine.
Experimental
Matched Description: … It is a precursor of spermine. …
ACR325
ACR325 is developed for the treatment of Parkinson’s disease and psychoses, including bipolar disorder, for which disease existing therapies have only limited effect and considerable adverse side effects. ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses.
Investigational
Matched Description: … ACR325 is developed for the treatment of Parkinson’s disease and psychoses, including bipolar disorder …
Subasumstat
Subasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)).
Investigational
Matched Description: … NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of …
RO7300490
RO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist. RO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors).
Investigational
Matched Description: … in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of …
CMLVAX100
CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.
Investigational
Matched Description: … It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial. …
Nitarsone
Nitarsone is an organoarsenic compound. It is used as an additive in poultry feed to improve weight gain and feed efficiency, while preventing blackhead disease. It is marketed as Histostat by Zoetis, a publicly traded subsidiary of Pfizer.
Vet approved
Matched Description: … It is marketed as Histostat by Zoetis, a publicly traded subsidiary of Pfizer. …
Deferitazole
Deferitazole is an iron chelator. It has been used in trials studying the treatment and basic science of Beta-thalassemia, Hepatic Impairment, Impaired Renal Function, Transfusional Iron Overload, and Iron Overload Due to Repeated Red Blood Cell Transfusions.
Investigational
Matched Description: … It has been used in trials studying the treatment and basic science of Beta-thalassemia, Hepatic Impairment …
Zotiraciclib
Zotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma).
Investigational
Matched Description: … Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of …
PLX51107
PLX51107 is a potent and selective inhibitor of the bromodomain and extraterminal (BET) protein family.[A257246,A257251] PLX51107 is under investigation in clinical trial NCT04022785 (PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome).
Investigational
Matched Description: … PLX51107 is a potent and selective inhibitor of the bromodomain and extraterminal (BET) protein family …
OBE101
OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine. Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management...
Investigational
Matched Description: … repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of …
Pipendoxifene
ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer. Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment for metastatic breast cancer.
Investigational
Matched Description: … modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of …
TD-2749
TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome (C-IBS), opioid-induced constipation, functional dyspepsia and diabetic gastroparesis.
Investigational
Matched Description: … TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug …
Lonidamine
Lonidamine (LND) is a drug that interferes with energy metabolism of cancer cells, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK). In such way LND could impair energy-requiring processes, as recovery from potentially lethal damage, induced by radiation treatment and by some cytotoxic drugs.
Investigational
Matched Description: … Lonidamine (LND) is a drug that interferes with energy metabolism of cancer cells, principally inhibiting …
Bizalimogene ralaplasmid
Bizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And/or HPV-18 Related Anal or Anal/peri-anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2).
Investigational
Matched Description: … NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of …
Reproxalap
Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.
Investigational
Matched Description: … [L32990] NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome …
Pinatuzumab vedotin
Pinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)).
Investigational
Matched Description: … Pinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin …
Pegcrisantaspase
Pegcrisantaspase is under investigation in clinical trial NCT02257684 (A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)).
Investigational
Matched Description: … is under investigation in clinical trial NCT02257684 (A Dose Confirmation and Pharmacokinetic Study of …
COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection
COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection is an intradermal injection currently being investigated in the clinical trial NCT03348670 (Discovery Stage (Proof-of-concept) COVID-19 Antigen Presentation Therapeutic Biologics (COVID-19--AP) (AP-TP-Bio)) .
Investigational
Matched Description: … intradermal injection currently being investigated in the clinical trial NCT03348670 (Discovery Stage (Proof-of-concept …
IMM01
IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG 1 fusion protein. IMM01 is under investigation in clinical trial NCT05140811 (A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome).
Investigational
Matched Description: … [A257261] IMM01 is under investigation in clinical trial NCT05140811 (A Study of IMM01 Combined With …
AAV1-FS344
AAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor. It is being investigated for the treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and inclusion body myositis.[L46742, L46747, L46752]
Investigational
Matched Description: … It is being investigated for the treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, …
Pyruvaldehyde
An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals. [PubChem]
Experimental
Matched Description: … It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated …
Displaying drugs 7651 - 7675 of 8037 in total